



GOG PARTNERS CONNECTION

A Quarterly Newsletter
From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission that is dedicated to transforming the standard of care in gynecologic oncology.

The GOG Foundation, Inc. Announces Inclusion, Diversity, Equity and Access (IDEA) Initiative

Recently launched in July 2022, The GOG Foundation Inclusion, Diversity, Equity and Access (IDEA) Initiative is being led by Bhavana Pothuri, MD, Director of Diversity and Health Equity for Clinical Trials. The first priority of the initiative is to publish a manuscript with a joint statement on IDEA with the Society of Gynecologic Oncology (SGO) (*publication pending*).



The mission of the initiative is to educate the key stakeholders in the design and conduct of clinical trials in gynecologic oncology on why diversity in clinical trials is important, what barriers exist for patients from underrepresented racial and ethnic populations, and what steps healthcare professionals can take to mitigate racial/ethnic disparities and promote equity and justice to ensure clinical trial access for all.

The IDEA Initiative is currently working with the GOG Foundation Investigator's Council (IC) Clinical Trial Equity/Patient Advocacy subcommittee, led by Tashanna Myers, MD, to produce IDEA Education Modules addressing topics such as commitment to DEI, community engagement, protocol design, study conduct/accountability, and advocacy.



Be on the lookout for more exciting announcements from the IDEA Initiative!

SPECIAL RECOGNITION

ASCO Board of Directors Election

We are pleased to congratulate Dr. Kathleen Moore from

Stephenson Cancer Center at the University of Oklahoma, on her recent election to the ASCO Board of Directors as the Designated Surgical Oncologist Seat. She will begin a four-year term beginning in June 2023.



NRG Oncology NRG-GY018 Press Release

NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression Free Survival Outcomes for Women with Advanced or Recurrent Endometrial Cancer with the Addition of Pembrolizumab to Chemotherapy



NRG Oncology Phase III clinical trial, NRG-GY018, evaluating pembrolizumab in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma, regardless of mismatch repair status. A pre-specified interim analysis, conducted by an independent Data Monitoring Committee, demonstrates that pembrolizumab in combination with chemotherapy has a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy alone in both study cohorts, mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR). The full results of this trial will be presented at an upcoming scientific conference.

NRG-GY018, a randomized, blinded, placebo-controlled study, accrued 819 women with stage III-IV or recurrent endometrial cancer. Two independent cohorts were evaluated, patients with endometrial cancers that are dMMR and patients with endometrial cancers that are pMMR. Patients were randomly assigned to receive pembrolizumab combined with carboplatin and paclitaxel (for a planned six, 3-week cycles), followed by pembrolizumab maintenance (for up to fourteen, 6 week cycles) or placebo combined with carboplatin and paclitaxel, followed by placebo maintenance.

"Patients with advanced stage or recurrent endometrial cancer, the most common type of gynecologic cancer in the U.S., face a poor prognosis with limited treatment options. This is particularly notable in patients who progress after prior platinum-based adjuvant therapy with disease not amenable to curative surgery or radiation," stated Ramez Eskander, MD, of the University of California San Diego Moores Cancer Center and the Principal Investigator of the NRG-GY018 trial. "In this study, pembrolizumab in combination with carboplatin and paclitaxel resulted in a statistically significant and clinically meaningful improvement in PFS in both the dMMR and pMMR study populations. We look forward to presenting these exciting findings at an upcoming scientific congress."



[Click here](#) to view the full press release.

UPCOMING INDUSTRY MEETINGS

ESMO GYNAECOLOGICAL CANCERS ANNUAL CONGRESS



The 2023 ESMO Gynaecological Cancers Annual Congress will be held on **February 23-24, 2023** both in person in Barcelona, Spain and virtually.

ESMO Gynaecological Cancers has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.

[Click Here](#) for more information on the ESMO Gynaecological Cancers Annual Congress.

ESMO Gynaecological Cancers Scientific Co-Chairs

- Susana Banerjee, London, UK
- Domenica Lorusso, Rome, IT
- Bradley J. Monk, Phoenix, AZ, USA

Scientific Committee Members

- Robert Coleman, Houston, TX, USA
- Nicole Concin, Innsbruck, Austria
- Kosei Hasegawa, Saitama, Japan
- Ana Oaknin, Barcelona, Spain
- Isabelle Ray-Coquard, Lyon, France

SGO Annual Meeting



The 2023 SGO Annual Meeting will be held on **March 25 - 28, 2023** in Tampa, FL at the **Tampa Convention Center**.

The SGO Annual Meeting on Women's Cancer® is the premier educational and scientific event for those who treat and care for women with gynecologic cancer.

[Click Here](#) for more information on the SGO Annual Meeting.

ASCO Annual Meeting



The 2023 ASCO Annual Meeting will be held on **June 2 - 6, 2023** in Chicago, IL, at the **McCormick Place Convention Center**. This year's meeting is only available in person.

Join fellow oncology professionals at the 2023 ASCO Annual Meeting – a unique and unparalleled opportunity to connect with one of the largest, most diverse audiences in global cancer care.

[Click Here](#) for more information on the ASCO Annual Meeting.



The 2023 WAGO Annual Meeting will be held on **June 14 - 17 2023** in Monterey, CA at the **Hyatt Regency Monterey Hotel & Spa**.

[Click Here](#) for more information on the WAGO Annual Meeting.

ON DEMAND EDUCATION

The GOG Foundation, Inc. is thrilled to share that we have developed on demand educational opportunities in collaboration with Medscape Oncology.

Medscape
Oncology

Click the session title below to view these exciting sessions available today!

- [Endometrial Cancer Consult: Optimal Management Across the Disease Continuum](#)
- [Ovarian Cancer Consult: Adapting to PARP Inhibitors](#)
- [Minimizing Disparities in Gynecologic Cancers to Enhance Equitable Cancer Care](#)
- [A Clinical Case Symposium: PARP Inhibitors in Advanced Ovarian Cancer and the Impact on Survival](#)
- [Gynecologic Malignancies: Status Updates From the 2022 Annual Oncology Meeting in Chicago](#)
- [Virtual Grand Rounds: Staying Up to Date With Endometrial Cancer](#)

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 19 clinical trials

- 15 Ovary
- 1 Cervix
- 3 Endometrium



To search active trials visit our website by clicking Clinical Trials button below.

[Clinical Trials](#)

FEATURED CLINICAL TRIALS

GOG-3076 (OnPrime): Tip IGCS Abstract

Phase 3 study of efficacy and safety of Olvi-Vec and platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in platinum-

resistant/refractory ovarian cancer.

[Click Here](#) to read the full abstract.

GOG- 3087/ ENGOT-GYN5/ NCRI/ NXP00-101 Press Release



Nuvectis Pharma, Inc., a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a collaboration with the European Network of Gynecological Oncology Trial Groups ("ENGOT") and the GOG Foundation, Inc. ("GOG-F") to conduct the NXP800 Phase 1b clinical trial in ARID1A-mutated, ovarian clear cell and endometroid carcinomas in Europe and the United States.

Clinical data from the ongoing Phase 1a trial to date suggest that the emerging clinical profile of NXP800 can provide a good balance between systemic exposure, pharmacodynamic activity and tolerability, and we look forward to the initiation of the Phase 1b trial in the next few months.

[Click here](#) to read the full press release.

GOG-3081 (PRESERVE-004) Press Release



OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer (PROC) (PRESERVE-004, NCT5446298).

The patient was dosed at the Women's Cancer Care Associates, LLC, located in Albany New York. Dr. Joyce Barlin is the site Principal Investigator (PI). The study is sponsored by OncoC4, Inc., in collaboration with Merck (known as MSD outside the US and Canada) and the GOG Foundation, Inc.

"It is an exciting time for immunotherapy clinical trial research. I am incredibly grateful for the opportunity to serve as the Co-PI on this Phase 2 trial with Dr. Bradley Monk. We are thrilled to dose the first patient at our institution with this innovative immunotherapy combination, which hopes to address the unmet need in platinum-resistant ovarian cancer," said Dr. Joyce Barlin.

[Click Here](#) to read the full press release.

PHILANTHROPY

New Horizons Gynecologic Cancer Research Fund



The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for The GOG Foundation, Inc. Donations allow the GOG to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:

- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

[Support Our Mission](#)

LET'S GET SOCIAL

What GOG Means to Me

“ ”

GOG means research success and amazing people. GOG runs trials that provide novel effective treatments for patients with gynecologic malignancies. GOG is inclusive in mentoring our next generation of clinical trialists to be the best

“ ”

Thomas J. Herzog, MD
GOG Partners Associate Director
Clinical Director
Paul & Carolyn Flory Professor in Gynecologic Oncology
University of Cincinnati

GOG FOUNDATION
Promoting the prevention of cancer

GOG PARTNERS
A GOG Foundation Program

What GOG Means to ME

The GOG Foundation, Inc. launched a “What GOG Means to ME” social media campaign and we would like you to

Dana Chase
Arizona Center for Cancer Care

GOG FOUNDATION
SOCIAL AGENT

THE GOG FOUNDATION, INC
DINNER MEETING
JANUARY 26, 2023

Become a GOG Social Media Agent

The GOG Foundation is looking for members that are savvy with social media to become GOG Social Media

participate.

As a participant in this campaign, you will be highlighted on our social media feeds (Twitter, Instagram, LinkedIn and Facebook). If you would like to participate, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- **Quote:** No more than 35 words indicating what GOG means to you, examples can include: research, clinical trials, networking.
- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags:** Please provide how we can find you on each of the social platforms so we can tag you when we post.

Agents! Throughout the year our communications staff will invite our agents to participate in social media campaigns for meetings, education and special events. If you are interested in becoming a GOG Social Media Agent, please email Lindsey Moeller at lmoeller@gog.org and include the following information:

- **Current Headshot** (Jpg or PNG format)
- **Current Title/Role**
- **Institution**
- **Social Tags:** Please provide how we can find you on each of the social platforms so we can tag you when we post.



How Can We Help?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.